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Background and objective: The number of infused CD34+cells (CD34+i) has been associated with absolute
lymphocyte count (ALC) and the outcome undergoing autologous hematopoietic stem cell transplanta-
tion (HSCT) in patients with hematologic malignancies. The study's aim was to analyze the relationship
between CD34+i, ALC and prognosis in this patients.
Patients and method: Medical records of 163 patients receiving HSCT between 2005 and 2012 were
reviewed.
Results: We found signiﬁcant and inversely proportional relationship between the CD34+i and the days
required to reach ALC≥500/μl according to the regression line: days¼−0.981number of CD34+i+18.09.
Conclusions: We have obtained a predictive model of lymphocyte recovery based recovery of CD34+i.
& 2013 Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Autologous hematopoietic stem cell transplantation (HSCT),
consisting of high dose chemotherapy and subsequent infusion
of hematopoietic stem cells (CD34+cells) is a therapeutic proce-
dure used in many hematologic malignancies.
Following HSCT a complex immune reconstitution (IR) is
observed. When the infused CD34+cells (CD34+i) begin to pro-
liferate, an increase in peripheral blood cells is detected. Lympho-
cytes require more time than granulocytes in order to reestablish
their normal function during the early post-transplant period [1].
An absolute lymphocyte count (ALC) 4500/μl at day 15 post-
HSCT has been associated with a better prognosis in patients with
hematologic malignancies [2–4]. Moreover, the number of CD34+i
has been associated with ALC and clinical evolution. Hence, an
ALC≤500/μl on day 15 has been proposed as an independent risk
factor [3–6].
Our aim was to determine the inﬂuence of ALC, at day 15, in
predicting post-HSCT outcome in patients with non-Hodgkin
lymphoma (NHL), Hodgkin lymphoma (HL) and multiple myeloma
(MM) in terms of progression-free survival (PFS) and overall
survival (OS), and to analyze the relationship between the number
of CD34+i and the number of days required in order to reach
ALC≥500/μl as well as clinical evolution.omero Fernández).
ess under CC BY-NC-ND license.Materials and methods
Patients and samples
Medical records of a total of 163 patients with hematologic
malignancies receiving autologous-HSCT between January 2005
and March 2012 in our Hospital were reviewed. Patients with
incomplete follow-up data and/or absent blood count at day 15
were excluded (n¼7).
Autologous CD34+i during HSCT were obtained after bone
marrow mobilization through administration of granulocyte-
colony stimulating factor (G-CSF) with or without concomitant
chemotherapy. Collection of CD34+cells were performed using a
blood cell separator (CS-3000 Plus, Baxters). Flow cytometry
(FACScan, Becton Dickinsons) and CD34+ count guides (ISHAGE)
were followed.
A retrospective database was created, along with daily periph-
eral lymphocyte recounts until an ALC4500/μl was obtained.
Total number of days for endpoint (ALC4500/μl) along with ALC
at day 15 was determined.
Statistical methods
Patients were distributed into two groups depending on ALC
(4oro500/μL) at day 15 post-HSCT. Correlation between CD34+i
and time to ALC≥500/μ was analyzed using Spearman's correlation
coefﬁcient (r) and ANOVA test. OS and PFS were calculated
according to the Kaplan–Meier curves and compared by log-rank
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and CD34+i/Kg was performed by Cox regression in order to
determine Hazard ratio (HR) and Receiver Operating Characteristic
curves (ROC curves).
OS and PFS were calculated from infusion day until death/end
of follow-up, and disease relapse or progression respectively.
Median follow-up of the study was 134 weeks (range: 69–294).
Statistical signiﬁcance was established with a p value o0.05.
SPSS (version 12/15) was used.Results
Patient characteristics are detailed in Table 1.Table 1
Patient characteristics.
n¼163 %
Sex
Male 95 58.3
Female 68 41.7
Age, years
Median 49
Range 18–68
Hematologic malignancy
NHL 86 52.7
DLBCL 50
FL 19
NHL-T 19
MCL 3
MM 45 27.6
IgG 27
IgA 9
Light chain 6
Non secretor 3
HL 32 19.7
NE 29
MC 3
Stage at diagnosis
I 0 0
II 44 27
III 60 37
IV 59 36
Status disease pre-HCST
CR1 79 48.4
CR2 32 19.6
PR 37 22.5
PROG 15 9.5
Conditioning, NHL/HL
BEAC 18
BEAM 100
Conditioning, MM
Melphalan 45
CD34+i/Kg
Median 2.99106
Range 0.54–26.23
Days to ALC4500/ll
Median 14
Range 3–30
ALC (/ll) at day 15 post-HSCT
4500 97 59.5
o500 66 40.5
NHL indicates, non Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; FL,
follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; HL,
Hodgkin lymphoma; NE, nodular sclerosis; MC, mixed cellularity; CR1, ﬁrst
complete remission; CR2, second complete remission; PR, partial remission; PROG,
progression; BEAC, Carmustine plus Etoposide plus Citarabine and Cyclophospha-
mide; BEAM, Carmustine plus Etoposide plus Citarabine and Melphalan; ALC,
absolute lymphocyte count.Patients with ALC4500/μl, n¼94 (59.5%) had a higher PFS and
OS compared with those with ALC below the limit, n¼64 (40.5%):
PFS 67 months (CI95%: 60.5–72.5) vs. 23 months (CI95%: 15.1–
30.8), po0.001 and OS of 283.5 weeks (CI95%: 262.7–304.4) vs.
211.8 weeks (CI95%: 171.3–252.3), po0.001 (Fig. 1). We found a
signiﬁcant effect of disease state in OS, with a lower OS in patients
with partial remission (PR) pre-HSCT compared to ﬁrst complete
remission (CR1) with HR¼4.28 (IC¼1.39–13.2), p¼0.011 in
patients with NHL, HL and MM.
Median CD34+i was 2.99106/Kg (range: 0.54–26.23) and the
median of days required for an ALC≥500/μl was 14 (range: 3–30).
We found a signiﬁcant and inversely proportional relationship
between the number of CD34+i and the days required to reach ALC
≥500/ml in patients with NHL (r¼−0.625; po0.001), HL (r¼
−0.801; po0.001) and MM (r¼−0.662; po0.001) according to
regression line (Fig. 2): days¼−0.981number of CD34+i+18.09.
Moreover, CD34+i≥2.0106/Kg directly and signiﬁcantly
related to an ALC4500/μl on day 15: RR¼7.77; po0.001
(IC95%:5.55–90.25) and post-HSCT survival so that ALC4500/μl,
n¼97(59.5%) was associated with better PFS and OS, compared to
patients with lower ALC, n¼66 (40.5%): PFS 67 months (CI95%:
62–73) vs. 23 months (CI95%: 15–31) po0.001 and OS 82 months
(CI95%: 78–85) vs. 55 months (CI95%: 44–65) po0.001.
Univariate analysis showed a statistically signiﬁcant association
between ALC at day 15 and prognosis, with higher OS and PFS in
patients attaining ALC4500/μl. On the other hand, patients with
CD34+i≥2.0106/Kg showed a superior outcome, independent of
the lymphocyte count and a protective effect on progression with
an increase in PFS but no statistically signiﬁcant relationship
between CD34+i and OS. As expected, previous disease statelimit.
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Fig. 1. Patients with ALC4500/μl at day 15 post-HCST had a higher PFS and OS
compared with those with ALC below this limit.
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Fig. 2. Predictive model of lymphocyte recovery according to regression line: days¼
−0.981number of CD34+i+18.09.
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disease progression presenting with a worse OS and PFS than
those in CR1 pre-HSCT. No signiﬁcant differences on survival
between patients in CR2 and those in PR were observed. In our
experience, no signiﬁcant correlation was found between the
number of lines of therapy pre-HSCT and CD34 cell counts or
lymphocyte recovery.
Multivariate analysis for ALC, CD34+i, disease state, age and sex
showed that not reaching an ALC4500 at day 15 post-HSCT was an
adverse factor for PFS with HR¼7.72 (CI95%: 4.05–14.7), po0.001
and for OS with HR¼9.7 (CI95%: 3.1–30.34), po0.001. In this series,
we additionally observed that infusing ≥4.38 CD34+106/Kg was
associated with better survival in all groups, p¼0.015 and HR¼0.27
(CI95%: 0.094–0.774). Additionally, disease progressionwas found to
be a statistically signiﬁcant risk factor when compared to patients
on CR1 pre-HSCT with HR¼4.28 (CI95%: 1.39–13.2), p¼0.011 but no
signiﬁcant differences were detected between patients with PR or
CR2 with respect to those achieving CR1 with HR¼1.59(CI95%:
0.53–4.75), p¼0.400 and HR¼1.03 (CI95%: 0.30–3.52), p¼0.100,
respectively. No statistically signiﬁcant differences could be found
between age or sex and ALC at day 15 with HR¼1.01 (CI95%: 0.99–
1.04), p¼0.200 and HR¼1.76 (CI95%: 0.76–4.05), p¼0.180,
respectively.Discussion
In accordance with the results, we have been able to determine
the existence of several factors with an impact on outcome after
autologous HSCT. Additional variables have been reported [5–7]
but detailed description of every single prognostic factor appar-
ently involved in post-transplant evolution was beyond the scope
of this study.
In accord with other authors [3–7], patients in our study with
localized disease at diagnosis showed better outcome compared to
those whose disease was in an advanced stage. Furthermore,
patients in CR1 or CR2 pre-HSCT showed better survival rates
than those who presented with disease progression. Nevertheless,
in contrast with other authors [6,7], there did not seem to be anysigniﬁcant difference in prognosis between patients in PR and
those who achieved CR2 pre-HSCT.
Porrata et al. were the ﬁrst to describe prognostic signiﬁcance
of early ALC in patients with HM undergoing HSCT [2–5] and we
conﬁrmed that. Some authors have attributed this improvement in
survival to a decrease in infection susceptibility in the subgroup of
patients who managed to attain an early lymphocytic reconstitu-
tion (ELR) after HSCT [1,2]. Even though we did not speciﬁcally
analyze infection risk in our patients, we proposed that such a
relation can be responsible for this observation.
Developing a means to predict ELR (to express as ALC) after
HSCT could be of great use during transplantation. In order to try
to prove this point, we obtained a predictive model capable of
estimating total days for ELR according to CD34+i at day 0. Late
ALC (after day 15) can probably be associated with a greater
incidence of infections due to impaired immunity and, hence, a
worse prognosis [6–8]. Consequently, pre-transplant knowledge of
lymphocyte reconstitution dynamics should be able to deﬁne
which subgroup of patients could beneﬁt from early antibiotic
therapy, and which optimal CD34+i count should be reached in
order to guaranty ELR. In this sense, we propose early ALC as a
predictive prognostic marker. Additionally, we found a positive
correlation between CD34+i and dynamics of lymphocyte recov-
ery, especially in patients with HL.
We have obtained a regression line as a predictive model of
lymphocyte recovery, not previously described, based on CD34+i
and it could be used as a prognosis tool in this patients. None-
theless, future prospective studies analyzing lymphocyte subpo-
pulations are needed to achieve a better understanding of IR.
There are still many questions that remained unanswered.Role of the funding source
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